Becton, Dickinson and VP Jeffrey S. Sherman Sells 7,877 Shares (BDX)
Becton, Dickinson and (NYSE:BDX) VP Jeffrey S. Sherman sold 7,877 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $120.24, for a total value of $947,130.48. Following the completion of the transaction, the vice president now directly owns 27,768 shares in the company, valued at approximately $3,338,824. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Becton, Dickinson and (NYSE:BDX) traded down 0.89% on Tuesday, hitting $119.26. The stock had a trading volume of 506,329 shares. Becton, Dickinson and has a 1-year low of $94.25 and a 1-year high of $120.66. The stock’s 50-day moving average is $115.8 and its 200-day moving average is $112.7. The company has a market cap of $23.042 billion and a P/E ratio of 25.11.
Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.45 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.50 by $0.05. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.09 billion. During the same quarter last year, the company posted $1.39 earnings per share. Becton, Dickinson and’s revenue was up 3.6% compared to the same quarter last year. Analysts expect that Becton, Dickinson and will post $6.25 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $0.545 per share. This represents a $2.18 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Thursday, June 5th.
Several analysts have recently commented on the stock. Analysts at SunTrust raised their price target on shares of Becton, Dickinson and from $128.00 to $138.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Becton, Dickinson and from $109.00 to $113.00 in a research note on Friday, May 9th. They now have a “sector perform” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Becton, Dickinson and from $108.00 to $110.00 in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $109.62.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.